IBM heavy money pressure artificial intelligence medical: Is it right or wrong?
Paul Tang is accompanying his wife who has just finished a knee replacement surgery in the hospital. Every year, there are about 700,000 people in the United States doing this operation. Tang himself is also a primary care physician. He asked the doctor how his wife could return to normal life based on his past experience. But doctors always blur their words and cannot give a clear answer. "I finally realized that he didn't know it." Tang quickly understood that most doctors don't really know when a patient can recover and return to normal life, which is the most important thing for patients.
Tang still treats patients from the perspective of a physician, but he is also the chief health reform officer at IBM's Watson Health. Watson Health is a Watson-owned business group that specializes in health care applications, a machine learning system that IBM values. Tang pointed out that Watson can convey information that doctors don't know. For example, it can tell the doctor how long the patient can recover, help the doctor to divide the information image and tissue samples, and determine the best treatment plan for the patient.
It is the infinite possibilities of these technologies that make health care the most sought-after application area for machine learning technology. According to market research firm CB Insights, at least 106 startups have entered the field since 2013 and have survived to this day.
But none of these startups have a Watson-level reputation. This is due to its 2011 quiz show "Jeopardy! The victory of the "and after the marketing of IBM is enough." But recently, news reports about Watson are mostly negative. The high-profile promotion of the MD Anderson Cancer Center has also ended this year. As IBM's revenues shrank and share prices fell, analysts questioned whether Watson could realize the value of previous promotions.
“Watson is a joke.†One of the founders of venture capital firm Social Capital, noted that technology investor Chamath Palihapitiya said on CNBC in May this year.
However, this series of criticism accusations seem to be based on Watson's technological flaws, most of which are aimed at IBM's expected time to achieve Watson's goal is too optimistic. In fact, it seems that the application of AI in the field of health care will be led by Watson Health in the future. If Watson does not seem to be doing well at the moment, one of the main reasons is that it also needs to "train" certain types of data. And the whole industry is not only the Watson family, but in fact this is a common problem faced by all companies in the field.
Will AI reform the medical field in the next five years?
Although the lack of data may slow down Watson's pace, the negative impact of IBM's competitors will certainly be greater. This is because the most important thing to get data is to work together with large health care organizations; but these big companies are usually very conservative in technology.
One thing, IBM is better than a group of startups, and even Apple and Google's heavyweight competitors, that is, newcomers to executives and IT leaders in large organizations. In comparison, the MD Anderson project is not important because IBM has a key advantage. IBM has successfully placed Watson in a number of medical centers, healthcare management teams, and life sciences companies, all of which can provide Watson with vital data to help Watson build the future of AI in the medical arena.
Infusion set,Disposable Syringe,Insulin Syringe,gauze roll,Cotton roll,Sterile Urine cup
FOSHAN PHARMA CO., LTD. , https://www.fs-pharma.com